Ascendis Pharma posts strong Q2 2026 with €339M revenue, boosts price target to $290 by RBC Capital.

Ascendis Pharma reported robust Q2 2026 results with total revenue of €339 million, driven by strong sales of its three main products: YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company achieved a net profit of €207 million and ended the quarter with a healthy cash position of €812 million, despite spending €56 million on share buybacks. RBC Capital reaffirmed its Outperform rating and raised the price target to $290, reflecting confidence in Ascendis Pharma's growth prospects fueled by increasing demand and successful product commercialization.